Lenvatinib

Excerpt

Lenvatinib is FDA-approved for the treatment of radioactive iodine-refractory differentiated thyroid cancer (DTC), unresectable or advanced hepatocellular carcinoma (HCC), advanced renal cell carcinoma (RCC), and advanced endometrial carcinoma. The multiple receptor tyrosine kinase inhibitor demonstrates potent antiangiogenic properties. The inhibition of the VEGF receptors prevents tumor angiogenesis, and the inhibition of FGFR, RET, PDGFRa, and KIT prevents further proliferation of malignant cells. The prescribing team should include primary care clinicians, oncologists, nurses, and pharmacists, crucial for early diagnosis, monitoring potential adverse effects, and optimizing dosage adjustments based on renal function, liver enzymes, body weight, and cardiac health. Routine monitoring for adverse effects like hypertension, cardiac impairment, QT interval prolongation, thyroid function changes, and reproductive considerations is necessary, along with patient education for better treatment outcomes and increased quality of life.